At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 463 enrolled
Drug / intervention
Famciclovir +1 moredrug
Likely dose
Famciclovir 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multicenter, Double-blind Study to Compare the Efficacy of Single-day Treatment (1000 mg b.i.d.) With Famciclovir Compared to That of Placebo in Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Immunocompetent Black Patients
In Brief
A Phase 4 clinical trial evaluating Famciclovir and Placebo for Genital Herpes. Completed, enrolled 463 participants across 43 sites in 2 countries.
Detailed Summary
This study will evaluate the safety and efficacy of single-day famciclovir episodic treatment in Black patients with recurrent genital herpes
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGenital Herpes
CountriesSouth Africa, United States
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2007
Enrollment StartJun 2007
Primary CompletionMar 2009
TodayJul 2026
First PostedMay 23, 2007
Enrollment StartJun 1, 2007
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 19.1 years ago
Interventions
Famciclovirdrug
oral; two 500 mg tablets twice a day; single day treatment
Placebodrug
oral; two tablets twice a day; single day treatment